The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Everolimus. The risk or severity of adverse effects can be increased when Levobunolol is combined with Empagliflozin. The risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinonide. The metabolism of Bromazepam can be decreased when combined with Cholecalciferol. The metabolism of Brompheniramine can be decreased when combined with Zucapsaicin. The metabolism of Fenofibrate can be decreased when combined with Darunavir. Hexobarbital may increase the hypotensive activities of Penbutolol. The risk or severity of adverse effects can be increased when Paliperidone is combined with Pramocaine. The therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methohexital. The metabolism of Umeclidinium can be decreased when combined with Midostaurin. The risk or severity of adverse effects can be increased when Alogliptin is combined with Cyclophosphamide. The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Benzydamine. Cilazapril may increase the hypotensive activities of Manidipine. The metabolism of Hydrocortisone can be decreased when combined with Nilotinib. Atomoxetine may increase the tachycardic activities of Isoetarine. Nialamide may increase the hypoglycemic activities of Rosiglitazone. The serum concentration of Fluticasone furoate can be increased when it is combined with Ethinyl Estradiol. The serum concentration of Atorvastatin can be decreased when it is combined with Colestipol. The risk or severity of adverse effects can be increased when Nepafenac is combined with Fluprednidene. The serum concentration of Prednisolone can be increased when it is combined with Ritonavir. The metabolism of Tesmilifene can be decreased when combined with Atazanavir. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Protriptyline. Loxoprofen may increase the hyperkalemic activities of Drospirenone. The risk or severity of adverse effects can be increased when Candesartan is combined with Tolfenamic Acid. The serum concentration of Proscillaridin can be increased when it is combined with Solithromycin. Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Indenolol. The serum concentration of Vincristine can be increased when it is combined with Prazosin. The metabolism of Carbinoxamine can be decreased when combined with Felodipine. The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasone. The risk or severity of adverse effects can be increased when Piritramide is combined with Cyclizine. The metabolism of Clonidine can be decreased when combined with Bupropion. The risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasol propionate. Sucralfate can cause a decrease in the absorption of Flucytosine resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuproxam. Methylecgonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Aloxiprin may increase the anticoagulant activities of Ethyl biscoumacetate. Rimexolone may increase the hypokalemic activities of Hydrochlorothiazide. Quinidine may increase the neuromuscular blocking activities of Vecuronium. The risk or severity of adverse effects can be increased when Bevantolol is combined with Floctafenine. The serum concentration of Vemurafenib can be increased when it is combined with Atazanavir. The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Piroxicam. Ketoprofen may decrease the antihypertensive activities of Hydralazine. The risk or severity of adverse effects can be increased when Heroin is combined with Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Harmaline. The serum concentration of Prednisone can be increased when it is combined with Ritonavir. Sertraline may increase the hyponatremic activities of Bendroflumethiazide. The risk or severity of adverse effects can be increased when Halothane is combined with Trandolapril. The serum concentration of Talinolol can be decreased when it is combined with Amobarbital. The serum concentration of Cyclosporine can be increased when it is combined with Saxagliptin. The risk or severity of adverse effects can be increased when Bromfenac is combined with Flunisolide. The metabolism of Bufuralol can be decreased when combined with Ketoconazole. Cyclosporine may increase the neuromuscular blocking activities of Pyrantel. The risk or severity of adverse effects can be increased when Nicergoline is combined with Felodipine. The serum concentration of Diethylstilbestrol can be decreased when it is combined with Eslicarbazepine acetate. The serum concentration of Deferiprone can be decreased when it is combined with Calcium Phosphate. The therapeutic efficacy of Repaglinide can be decreased when used in combination with Medroxyprogesterone acetate. Bisoprolol may decrease the bronchodilatory activities of Fenoterol. The metabolism of Antipyrine can be decreased when combined with Ketoconazole. Bufexamac may increase the anticoagulant activities of Troxerutin. The therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac. Nepafenac may increase the anticoagulant activities of Heparin. Zofenopril may increase the hyperkalemic activities of Drospirenone. The risk or severity of adverse effects can be increased when Ramipril is combined with Azelastine. Polymyxin B Sulfate may increase the neuromuscular blocking activities of Rocuronium. The risk or severity of adverse effects can be increased when Cocaine is combined with Chloral hydrate. The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clobetasone. Vilanterol may increase the QTc-prolonging activities of Cisapride. Ammonium chloride may increase the excretion rate of Bezitramide which could result in a lower serum level and potentially a reduction in efficacy. The risk or severity of adverse effects can be increased when Tamsulosin is combined with Metolazone. Brofaromine may increase the hypotensive activities of Betaxolol. Atracurium besylate may increase the anticholinergic activities of Aclidinium. Ketoprofen may decrease the antihypertensive activities of Bupranolol. The serum concentration of Methyltestosterone can be increased when it is combined with Ivacaftor. Mannitol may increase the nephrotoxic activities of Amrubicin. The serum concentration of Efavirenz can be decreased when it is combined with Fosphenytoin. The serum concentration of Dapoxetine can be increased when it is combined with Darunavir. Tubocurarine may increase the bradycardic activities of Oxprenolol. Carisoprodol may increase the sedative activities of Metyrosine. The risk or severity of adverse effects can be increased when Enflurane is combined with Clonidine. Ketoprofen may increase the nephrotoxic activities of Cyclosporine. The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dacarbazine. Bendroflumethiazide may increase the hypotensive activities of Ambrisentan. The metabolism of Timolol can be decreased when combined with Terbinafine. Succinylcholine may increase the arrhythmogenic activities of Proscillaridin. The metabolism of Levomilnacipran can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Fluprednidene is combined with Galantamine. Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. The risk or severity of adverse effects can be increased when Eprosartan is combined with Benzydamine. The risk or severity of adverse effects can be increased when Bromfenac is combined with Flumethasone. The metabolism of Lisuride can be decreased when combined with Iproclozide. The metabolism of Calcitriol can be decreased when combined with Delavirdine. Barbital may increase the hypotensive activities of Atenolol. Tolmetin may decrease the excretion rate of Spectinomycin which could result in a higher serum level. The therapeutic efficacy of Morphine can be increased when used in combination with Pargyline. Desflurane may increase the QTc-prolonging activities of Quinidine. Tamsulosin may decrease the vasoconstricting activities of Ergotamine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide. The metabolism of Antipyrine can be decreased when combined with Ritonavir. The metabolism of Selexipag can be decreased when combined with Losartan. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone. The serum concentration of Mibefradil can be increased when it is combined with Cimetidine. The metabolism of Ramelteon can be decreased when combined with Verapamil. The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tolfenamic Acid. The metabolism of Hydromorphone can be decreased when combined with Atazanavir. The risk or severity of adverse effects can be increased when Ferulic acid is combined with Cortisone acetate. Pirbuterol may increase the hypokalemic activities of Chlorothiazide. Atamestane may increase the hypokalemic activities of Quinethazone. The metabolism of Terbinafine can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoximetasone. Zimelidine may increase the hypoglycemic activities of Pioglitazone. The risk or severity of adverse effects can be increased when Sorafenib is combined with Atorvastatin. The therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorothiazide. The risk or severity of adverse effects can be increased when PTC299 is combined with Cortisone acetate. The metabolism of Enalapril can be decreased when combined with Itraconazole. The risk or severity of adverse effects can be increased when Tramadol is combined with Tetracaine. The metabolism of Testosterone can be decreased when combined with Capecitabine. The serum concentration of Topotecan can be increased when it is combined with Losartan. The risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone. The serum concentration of Sabarubicin can be decreased when it is combined with Amoxicillin. The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine. Calcium Acetate may increase the arrhythmogenic activities of Proscillaridin. The risk or severity of adverse effects can be increased when Bromfenac is combined with Azelastine. The metabolism of Tolbutamide can be decreased when combined with Fluorouracil. Metipranolol may increase the vasoconstricting activities of Dihydroergotamine. The serum concentration of Proscillaridin can be decreased when it is combined with Tobramycin. The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Prazosin. The metabolism of Sulfadiazine can be decreased when combined with Ticagrelor. The metabolism of Baricitinib can be decreased when combined with Clemastine. Tromethamine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. Salicylamide may decrease the antihypertensive activities of Alprenolol.